Hemab Therapeutics Holdings, Inc. Common Stock (COAG) — Defensive Interval Ratio

Latest as of December 2025: 3333 days

Hemab Therapeutics Holdings, Inc. Common Stock (COAG) has a Defensive Interval Ratio of 3333 days as of December 2025. Defensive assets of $97.51 Million (cash $-, short-term investments $97.51 Million, receivables $-) cover 3333 days of daily cash needs of $29.25K/day. For the complete balance sheet picture, see Hemab Therapeutics Holdings, Inc. Common balance sheet assets.

Defensive Interval Ratio

3333 days
Days of operational coverage

Defensive Assets

$97.51 Million
Cash + ST Investments + Receivables

Daily Cash Need

$29.25K
Current Liabilities ÷ 365

Current Liabilities

$10.68 Million
USD

Hemab Therapeutics Holdings, Inc. Common Stock Defensive Interval Ratio (2024–2025)

This chart shows how Hemab Therapeutics Holdings, Inc. Common Stock's Defensive Interval Ratio has evolved across 2 annual periods from 2024 to 2025. As of December 2025, the ratio stands at 3333 days, meaning defensive assets of $97.51 Million can fund 3333 days of operations without new revenue. Check financial resilience of Hemab Therapeutics Holdings, Inc. Common to evaluate the company's liquid asset resilience ratio.

Annual Defensive Interval Ratio for Hemab Therapeutics Holdings, Inc. Common Stock (2024–2025)

The table below presents the year-by-year Defensive Interval Ratio for Hemab Therapeutics Holdings, Inc. Common Stock from 2024 to 2025, covering 2 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year.

Year DIR (days) Defensive Assets (USD) Daily Cash Need Cash ST Investments Change (days)
2025 3333 days $97.51 Million $29.25K/day $- $97.51 Million ▲ +2574 days
2024 760 days $13.92 Million $18.32K/day $- $13.92 Million
DIR = (Cash + Short-term Investments + Net Receivables) / (Daily Cash Expenses)